Letermovir Prophylaxis for CMV Infection in Haplo-HSCT Recipients: Single-center Data in China
A legfontosabb adatok
- Ki végzi
- The First Affiliated Hospital of Soochow University
- Hol
- Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Befejeződött
- Résztvevők
- 200 fő vett részt
- Kezdés
- 2023. ápr. 1.
- Befejezés
- 2025. jan. 10.
- A vizsgálat típusa
- Megfigyeléses
- A vizsgált kezelések
- Letermovir
- A regiszteradat frissítve
- 2025. február 19.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 6 feltétel megnézéseKevesebb
Ki vehet részt
- Haplo-SCT candidate (adult) who has decided to primary transplant and is willing to participate in the study
- The haplo-SCT candidate (adult) should be CMV seropositive recipients
Ki nem vehet részt
- CMV-seronegative patient receiving a negative CMV donor graft
- Patients having active CMV DNAemia at the time of letermovir initiation
- Patient having signed the informed consent but not grafted
- Patient recruited in a clinical study on an anti-CMV trial
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
In the 30 years of fighting CMV infection, the mortality rate among HSCT patients has significantly reduced. Now, the focus is on improving the prognosis of HSCT patients and preventing CMV infection. The emergence of letermovir has provided a new opportunity in this regard. Letermovir, the only drug approved for CMV infection prevention in HSCT patients, works by inhibiting the CMV DNA terminase complex. Phase III studies have shown that letermovir significantly reduces CMV infection and all-cause mortality after HSCT, without increasing myelosuppression or nephrotoxicity. Real-world studies have further confirmed its efficacy in reducing CMV infection rates and antiviral use. Letermovir's global success has not yet been fully realized in China, where it is still in its early stages of use.
A vizsgálat csoportja
- 200 haplo-HSCT recipients who are CMV seropositive
The study consists 200 cases CMV-R+ adult (\>18 years) recipients of haplo-HCT. All patients will receive letermovir prophylaxis. Consider a simple interim analysis of the experimental group could be arranged after 150 patients are enrolled if necessary. Supportive care is provided by institutional standards of care (e.g., acyclovir for herpes simplex virus and varicella zoster virus prevention). Letermovir prophylaxis is started on day 0 or no longer than 28 days after transplantation. During the study period, letermovir 480 mg PO/IV once daily (or 240 mg per day in patients taking cyclosporine) was administered from day 0 to day +100 post-HCT. CMV monitoring and preemptive therapy were performed according to local protocol. Plasma CMV viral load (VL) is monitored by quantitative CMV PCR, starting on day +7 and continued weekly until week 6, then every 2-4 weeks for months until week 24.
Kezelés: Letermovir
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Letermovir Prophylaxis for Cytomegalovirus Infection in Haploidentical Allogeneic Hematopoietic Cell Transplant Recipients: Single-center Real-world Data in China
- Publikációk
- Letermovir for CMV prophylaxis after haploidentical HSCT: A prospective study of direct and indirect effects.International journal of antimicrobial agents, 2026
- A regiszteradat frissítve
- 2025. február 19.